Get access

The economic impact of cognitive impairment in Parkinson's disease

Authors

  • Corinna Vossius MD, PhD,

    Corresponding author
    1. Department of Neurology, Stavanger University Hospital, Stavanger, Norway
    2. Norwegian Centre for Movement Disorders, Stavanger University Hospital, Stavanger, Norway
    3. Stokka Teaching Nursing Home, Stavanger, Norway
    • Department of Neurology, Stavanger University Hospital, Box 8100, N-4068 Stavanger, Norway
    Search for more papers by this author
  • Jan P. Larsen MD, PhD,

    1. Department of Neurology, Stavanger University Hospital, Stavanger, Norway
    2. Norwegian Centre for Movement Disorders, Stavanger University Hospital, Stavanger, Norway
    Search for more papers by this author
  • Carmen Janvin PhD,

    1. Department of Psychiatry, Stavanger University Hospital, Stavanger, Norway
    Search for more papers by this author
  • Dag Aarsland MD, PhD

    1. Centre for Age-Related Medicine, Stavanger University Hospital, Stavanger, Norway
    2. Department of Psychiatry, Akershus University Hospital, University of Oslo, Norway
    Search for more papers by this author

  • Relevant conflicts of interest/financial disclosures: Nothing to report. Full financial disclosures and author roles may be found in the online version of this article.

Abstract

Background:

We investigated to what extent cognitive impairment and dementia were related to the direct medical and nonmedical costs in Parkinson's disease.

Methods:

Sixty-one patients with Parkinson's disease from a population-based cohort were assessed for motor and cognitive symptoms in 1993, 1997, and 2001. Data on use of health care and social services were collected.

Results:

The costs of patients with dementia were 3.3 times higher (€34,980) than those of nondemented patients (€10,626) per year of survival. Institutional care was the largest cost factor, representing 67% of the costs. Cognitive functioning predicted direct costs by 29.4%. Cognitive decline was associated with increased costs, even in nondemented subjects.

Conclusions:

Our findings suggest that dementia has a substantial impact on direct costs in Parkinson's disease, mainly due to high costs for institutional care. In addition, there were indications that even patients with mild cognitive impairment have higher nonmedical costs. © 2011 Movement Disorder Society

Ancillary